SIRION Biotech, Sanofi Partner to Revolutionise Gene Therapy Treatments - Pharmaceutical Technology
Join Our Newsletter - Get important industry news and analysis sent to your inbox – sign up to our e-Newsletter here

SIRION Biotech, Sanofi Partner to Revolutionise Gene Therapy Treatments

World leader in viral vector-based gene delivery technologies for gene & cell therapy, SIRION Biotech, is pleased to announce that it signed a license and collaboration agreement with global biopharmaceutical company Sanofi to develop improved tissue-selective adeno-associated virus (AAV) vectors to realise effective gene therapy treatments for human major organ-affecting disorders.

AAV vectors are a promising and clinically validated gene delivery platform for the potential treatment of a variety of human diseases. Sanofi, together with SIRION Biotech and Prof. Dirk Grimm, a world-renowned and pioneering scientist in the field of AAV biology and application working at Heidelberg University Hospital (Germany), will combine their proprietary technology platforms to create the next generation of AAV vectors. The goal of this collaboration is to develop new and modified AAV capsids that exhibit a safe product profile with improved specificity and higher gene delivery efficiency.

“This partnership adds to our expanding toolbox of technologies in the important, emerging area of gene therapeutics,” said Dr Christian Mueller, global head of genomic medicine at Sanofi. “Leveraging our expertise in virus-based vaccine and viral vector manufacturing together with Prof. Grimm’s cutting-edge AAV capsid evolution technology and SIRION’s expertise and capabilities in AAV vector manufacturing will allow us to better address unmet medical needs and open new frontiers for drug discovery in genomic medicine.”

“We are delighted to be collaborating with Sanofi,” stated Christian Thirion, PhD, CEO and Co‑founder of SIRION. “Sanofi is an ideal partner with decades-long experience in treating a multitude of disorders and exploring viral vectors as a therapeutic modality. AAV vectors with improved efficacy can enable quickly entering into clinical trials with efficient, safe low doses and scalable therapeutic candidates and can expand the impact of gene therapies.” Sabine Ott, Senior Vice President BD & Licensing at SIRION added: “We believe that through this exclusive partnership with Sanofi within these large disease fields, AAV-based gene therapies will provide novel treatment options to many millions of patients worldwide suffering from these diseases”.

For more information, please fill out the enquiry form attached to this page.

More About This Company